Evidence mapPaperPMID 22580991Full record

ArticleDiabetologia2012

HbA(1c) variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2.

A Sugawara, K Kawai, S Motohashi, K Saito, S Kodama, Y Yachi, R Hirasawa, H Shimano, K Yamazaki, H Sone

Erratum issued Registry-linked trialOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT02879409 (Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population), which is not on this map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
6.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02879409 naactive not recruitingstarted 2016, after this paper: background citation

Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?

Ran2016Enrolled150Registered outcomes4Posted comparisons0ConditionsDiabetes Mellitus Type 2Armsdapagliflozin, Gliclazide, human insulin, liraglutide, Metformin
Open the trial in the graph
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. The Association of HbADiabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Article
  7. Observational
  8. Observational
  9. Long-term Visit-to-Visit Variability in Hemoglobin AAmerican journal of kidney diseases : the official journal of the National Kidney Foundation · 2023
    Observational
  10. Article
  11. Observational
  12. Fasting Glucose Variation Predicts Microvascular Risk in ACCORD and VADT.The Journal of clinical endocrinology and metabolism · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links.International journal of physiology, pathophysiology and pharmacology · 2019
    Review
  20. Association of HbAInternational journal of molecular sciences · 2018
    Article
4 · The record

Corrections and comments

  • Erratum issued
5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

A SugawaraDepartment of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, 3-2-7 Miya-machi, Mito, Ibaraki, Japan, 310-0015.
K Kawai
S Motohashi
K Saito
S Kodama
Y Yachi
R Hirasawa
H Shimano
K Yamazaki
H Sone
University of Tsukuba · JPMito Saiseikai General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisThe aim of this study was to examine the association between HbA(1c) variability and the development of microalbuminuria as defined by an albumin/creatinine ratio ≥ 3.4 mg/mmol (≥ 30 mg/g) in at least two of three consecutive urine samples in Japanese patients with type 2 diabetes.

methodsHbA(1c) level was measured in 812 serially registered normoalbuminuric adults aged 21-79 years with type 2 diabetes. After registration, a 1-year period to establish baseline values for mean HbA(1c) and HbA(1c) variability (measured as the intrapersonal SD of serially collected HbA(1c)) was decided upon. The association between HbA(1c) variability and the development of microalbuminuria was determined by Cox regression analysis after adjustment for other risk factors for microalbuminuria.

resultsMicroalbuminuria occurred in 193 patients during the observation period of (mean ± SD) 4.3 ± 2.7 years. Even after adjustment for mean HbA(1c), HbA(1c) variability was a significant predictor of microalbuminuria independently of the mean HbA(1c); the HR for every 1% (95% CI) increase in mean HbA(1c) was 1.22 (1.06, 1.40) (p = 0.005), and that for HbA(1c) variability was 1.35 (1.05, 1.72) (p = 0.019). The effects of these two variables were quite similar when 1 SD was used; the HR for every 1 SD increase (95% CI) in HbA(1c) was 1.23 (1.07, 1.43) (p = 0.005), and that for HbA(1c) variability was 1.20 (1.03, 1.39) (p = 0.019). CONCLUSIONS/

interpretationHbA(1c) variability affects the development of microalbuminuria independently of mean HbA(1c) in type 2 diabetes. Further studies should be performed to evaluate the influence of HbA(1c) variability on other complications and in individuals of other ethnicities with type 2 diabetes.

Indexed as

AlbuminuriaAsian PeopleBlood GlucoseCreatinineDiabetes Mellitus, Type 2Diabetic AngiopathiesDiabetic NephropathiesFemaleGlycated HemoglobinHumansMaleMiddle AgedPredictive Value of TestsProportional Hazards ModelsRegistriesRisk FactorsBlood GlucoseCreatinineGlycated Hemoglobinhemoglobin A1c protein, humanSerum Albumin

Identifiers

PMID22580991
OpenAlexW2167161575

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.